Another two phase I trial evaluating the safety of RMC-4630 monotherapy (NCT03634982) and in combination with pembrolizumab (NCT04418661) in advanced solid tumor patients presented in the AACR ANNUAL MEETING 2020 showed that the combination of RMC-4630 with cobimetinib has acceptable tolerability, and tumor reduction was observed in three of eight patients with KRAS-mutant colorectal cancer, including one unconfirmed PR at the data cut-off (86). This evidence concerns the gene KRAS and colorectal cancer.